To this end, we acquired two datasets which contained the transcriptional profiles and treatment information of urothelial carcinoma patients receiving anti-PD-L1 immunotherapy and melanoma patients receiving anti-PD1 immunotherapy. This evidence concerns the gene CD274 and urothelial carcinoma.